Monarch Mining Reports its Results for the Quarter Ended March 31, 2021

PR Newswire

MONTREAL, May 13, 2021 /PRNewswire/ – MONARCH MINING CORPORATION (“Monarch” or the “Corporation“) (TSX: GBAR) (OTCMKTS: GBARF) reported its results today for the quarter and 141-day period ended March 31, 2021. Amounts are in Canadian dollars unless otherwise indicated.

Summary of financial results


(In dollars, except per share data)

 


THREE MONTHS ENDED



MARCH
31



2021

141-DAY PERIOD ENDED
MARCH 31

2021

Administrative expenses


585,444

585,444

Care and maintenance expenses


962,859

962,859

Exploration expenses


1,242,142

1,242,142

Net loss


(2,760,651)

(2,760,651)

Basic and diluted net loss


(0.05)

(0.08)


(In dollars)


MARCH 31, 2021

Cash and cash equivalents

19,013,624

Total assets

61,211,859

Non current liabilities

12,906,332

Shareholders’ equity

46,461,437

 

“These are our financial results for a full quarter following the closing of the Yamana Gold Inc. transaction and our January 26 listing as the new Monarch Mining Corporation entity,” said Jean-Marc Lacoste, President and CEO of Monarch. “We started the year strong, with major drilling programs on the Beaufor Mine, McKenzie Break and Croinor Gold properties, which are still ongoing. We also updated the mineral resource estimate technical reports on the Beaufor Mine, McKenzie Break and Swanson projects, which showed clear growth in the value of our mining assets. We expect the new resource estimate for the Beaufor Mine, which will include the results from the latest drilling programs, to further increase the potential value of the deposit.”

“We are still aiming to restart the Beaufor mine within the next 12 months in a gold market that remains strong. During the quarter, we also upgraded our technical team by adding experienced people who will help make Monarch a success. In addition, our strong financial position enables us to move forward with our advanced high-grade gold projects, for which we have high hopes,” Mr. Lacoste added.

About Monarch
Monarch Mining Corporation (TSX: GBAR) is a fully integrated mining company that owns four advanced projects, including the fully permitted past-producing Beaufor Mine, which has produced more than 1 million ounces of gold over the last 30 years. Other advanced assets include the Croinor Gold, McKenzie Break and Swanson properties, all located near Monarch’s wholly owned and fully permitted Beacon 750 tpd mill. Monarch owns 28,725 hectares (287 km2) of mining assets in the prolific Abitibi mining camp that host 588,482 ounces of combined measured and indicated gold resources and 329,393 ounces of combined inferred resources.

Forward-Looking Statements
The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarch’s actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this press release.


www.monarchmining.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/monarch-mining-reports-its-results-for-the-quarter-ended-march-31-2021-301290744.html

SOURCE Monarch Mining Corporation

Hycroft Announces Date Of First Quarter 2021 Financial And Operating Results And Conference Call

PR Newswire

DENVER, May 13, 2021 /PRNewswire/ — Hycroft Mining Holding Corporation (Nasdaq: HYMC) (“Hycroft” or the “Company”), a gold and silver producer operating the Hycroft Mine in the world-class mining region of Northern Nevada, plans to provide financial and operating results for the quarter ended March 31, 2021 on Monday, May 17, 2021 before market open.  A conference call to discuss those results will also be held on May 17, 2021 at 9:00 am ET (6:00 am PT). 


Conference Call – May 17, 2021 / 9:00 am ET (6:00 am PT)

To access the call, please dial:

Canada & US toll–free – 1-833-943-1683
Outside of Canada & US – 1–210-874-7692

Conference ID: 9129968

Please note that a recording of the call will be archived on our website at www.hycroftmining.com.


About Hycroft Mining Holding Corporation

Hycroft is a US-based, gold and silver producer operating the Hycroft Mine located in the world-class mining region of Northern Nevada. The Hycroft Mine ranks among the top 20 largest primary gold deposits in the world and is the second largest in the United States.


www.hycroftmining.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hycroft-announces-date-of-first-quarter-2021-financial-and-operating-results-and-conference-call-301290720.html

SOURCE Hycroft Mining Holding Corporation

Vertex Announces First Quarter 2021 Financial Results

KING OF PRUSSIA, Pa., May 13, 2021 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced financial results for its first quarter ended March 31, 2021.

“Our strong start to 2021 reflects the trust our customers have in us to help them navigate today’s complex and dynamic commerce landscape. The entire team is laser focused on our mission to enable every business to transact, comply and grow with confidence,” said David DeStefano, Vertex President and Chief Executive Officer. “As tax revenues continue to be a key part of our global economic recovery, the mission-critical role of our solutions to enable growth and reduce tax compliance friction will only continue. The investments we are making in our people and technology keep us well-positioned to seize these opportunities with innovative and differentiated solutions.”

First Quarter 2021 Financial Results

  • Total revenues of $98.2 million, up 10.1% year-over-year.
  • Software subscription revenues of $83.3 million, up 9.9% year-over-year.
  • Annual Recurring Revenue of $320.1 million, up 12.6% year-over-year.
  • Operating income of $2.1 million, compared to an operating loss of $(28.2) million for the same period prior year. Non-GAAP operating income of $15.4 million, up 23.6% year-over-year.
  • Net income of $2.3 million, compared to a net loss of $(29.1) million for the same period prior year. Non-GAAP net income of $11.0 million, compared to $11.6 million for the same period prior year.
  • Net income (loss) per basic Class A and Class B share was $0.02, compared to $0.00 and $(0.24), respectively, for the same period prior year. Net income (loss) per diluted Class A and Class B share was $0.01, compared to $0.00 and $(0.24), respectively, for the same period prior year.
  • Non-GAAP diluted EPS was $0.07, compared to $0.09 for the same period prior year.
  • Adjusted EBITDA of $18.2 million, up 18.9% year-over-year. Adjusted EBITDA margin of 18.5%, up 140 basis points year-over-year.

Vertex Chief Financial Officer John Schwab said, “We continue to execute and have delivered another strong quarter of performance. We remain confident in the strength of our business model, and plan to continue investing in our sustainable, long-term growth as CFOs and CIOs around the world face increased business and regulatory complexity. We believe the investments we are making to accelerate go-to-market, expand our partnerships, deliver new products, and enable great customer experiences are adding positive momentum to our business.”

Definitions of certain key business metrics and the non-GAAP financial measures used in this press release and reconciliations of such measures to their nearest GAAP equivalents are included below under the headings “Definitions of Certain Key Business Metrics” and “Use and Reconciliation of Non-GAAP Financial Measures.”

Recent Business Highlights

  • Acquired Taxamo, a cloud-based pioneer in tax and payment automation for global e-commerce and marketplaces on May 12, 2021. The purchase price for Taxamo was approximately $200 million in an all cash transaction. This acquisition supports and accelerates our growth strategies across ecommerce platforms and marketplaces in the enterprise and mid-market in Europe and North America, and among our existing global customers. The acquisition is a strategic opportunity that we believe will provide accretive revenue growth.
  • Acquired the assets of edge-computing startup, Tellutax, on January 25, 2021, enabling the next generation of tax technology solutions to be delivered seamlessly at the point of need with increased scalability and simplified management.
  • Announced a partnership with BigCommerce, a proven e-commerce leader, to deliver sales and use tax automation to the BigCommerce Apps Marketplace.
  • Introduced the Vertex® Indirect Tax Accelerator for Oracle Fusion Cloud Enterprise Resource Planning.
  • Net Revenue Retention Rate was 105% in the first quarter of 2021 as compared to 106% in the fourth quarter of 2020.
  • Announced the hiring of Yvette Burton as Chief People Innovation Officer, an executive responsible to shape the company’s global strategic workforce planning efforts and lead organizational programs to advance inclusion and diversity.

Financial Outlook

For the second quarter of 2021, the Company currently expects:

  • Revenues in the range of $99.0 million to $100.0 million, representing growth of 8.5% to 9.6% from the second quarter of 2020; and
  • Adjusted EBITDA in the range of $15.5 million to $16.5 million, representing a decrease of $6.0 million to $5.0 million from the second quarter of 2020.

The Taxamo acquisition closed on May 12, 2021. The above guidance for the second quarter of 2021 includes the impact of the acquisition, which includes a contribution of $0.5 million to revenues and $0.5 million decrease to Adjusted EBITDA.

For the full-year 2021, the Company currently expects:

  • Revenues in the range of $410 million to $414 million, representing growth of 9.4% to 10.5% from the full-year 2020; and
  • Adjusted EBITDA in the range of $66 million to $70 million, representing a decrease of $12.4 million to $8.4 million from the full-year 2020 due to the acceleration of our growth investments.

The full-year 2021 guidance reflects the impact of the Taxamo acquisition for the remainder of the year, which includes the contribution of $9.0 million to revenues and a $2.0 million decrease to Adjusted EBITDA primarily attributable to integration costs. We expect Taxamo to have a more significant impact on our 2022 revenues due to the timing of the acquisition and the tailwinds from new and pending marketplace facilitator VAT regulations. Notably, such regulations are already effective in the United Kingdom and are scheduled to go into effect throughout the European Union in July 2021.

Certain non-GAAP financial measures included in our financial outlook were not reconciled to the comparable GAAP financial measures because the GAAP financial measures are not accessible on a forward-looking basis. The Company is unable to reconcile these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures without unreasonable efforts because the Company is currently unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP financial measures for these periods but would not impact the non-GAAP financial measures. Such items may include stock-based compensation charges, depreciation and amortization of capitalized software costs and acquired intangible assets, severance, and other items. The unavailable information could have a significant impact on the Company’s GAAP financial results. The foregoing forward-looking statements reflect the Company’s expectations as of today’s date. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. The Company does not intend to update its financial outlook until its next quarterly results announcement.

Important disclosures in this earnings release about and reconciliations of historical and forward-looking non-GAAP financial measures to the nearest corresponding GAAP equivalents are provided below under “Use and Reconciliation of Non-GAAP Financial Measures.”

Conference Call and Webcast Information

Vertex will host a conference call to discuss the first quarter 2021 financial results on May 13, 2021 at 8:30 a.m. Eastern Time (“ET”). The conference call can be accessed live over the phone by dialing 1-877-407-4018, or for international callers 1-201-689-8471. A replay will be available from 11:30 a.m. ET on May 13, 2021, through May 27, 2021, by dialing 1-844-512-2921, or for international callers 1-412-317-6671. The replay passcode will be 13718842.

The call will also be webcast live from Vertex’s investor relations website at https://ir.vertexinc.com. Following the completion of the call, a recorded replay of the webcast will be available on the website.

About Vertex

Vertex, Inc. is a leading global provider of indirect tax software and solutions. The Company’s mission is to deliver the most trusted tax technology enabling global businesses to transact, comply and grow with confidence. Vertex provides cloud-based and on-premise solutions that can be tailored to specific industries for every major line of indirect tax, including sales and consumer use, value added and payroll. Headquartered in North America, and with offices in South America and Europe, Vertex employs over 1,200 professionals and serves companies across the globe. More information can be found at www.vertexinc.com.

Forward Looking Statements

Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. Forward-looking statements are based on Vertex management’s beliefs, as well as assumptions made by, and information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to: potential effects on our business of the COVID-19 pandemic; our ability to attract new customers on a cost-effective basis and the extent to which existing customers renew and upgrade their subscriptions; our ability to sustain and expand revenues, maintain profitability, and to effectively manage our anticipated growth; our ability to identify acquisition targets and to successfully integrate and operate acquired businesses; our ability to maintain and expand our strategic relationships with third parties; and the other factors described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities Exchange Commission (“SEC”). Copies of such filing may be obtained from the Company or the SEC.

All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances.

Definitions of Certain Key Business Metrics


Annual Recurring Revenue (“ARR”)

We derive the vast majority of our revenues from recurring software subscriptions. We believe ARR provides us with visibility to our projected software subscription revenues in order to evaluate the health of our business. Because we recognize subscription revenues ratably, we believe investors can use ARR to measure our expansion of existing customer revenues, new customer activity, and as an indicator of future software subscription revenues. ARR is based on monthly recurring revenues (“MRR”) from software subscriptions for the most recent month at period end, multiplied by twelve. MRR is calculated by dividing the software subscription price, inclusive of discounts, by the number of subscription covered months. MRR only includes customers with MRR at the end of the last month of the measurement period.


Net Revenue Retention Rate (“NRR”)

We believe that our NRR provides insight into our ability to retain and grow revenues from our customers, as well as their potential long-term value to us. We also believe it demonstrates to investors our ability to expand existing customer revenues, which is one of our key growth strategies. Our NRR refers to the ARR expansion during the 12 months of a reporting period for all customers who were part of our customer base at the beginning of the reporting period. Our NRR calculation takes into account any revenues lost from departing customers or customers who have downgraded or reduced usage, as well as any revenue expansion from migrations, new licenses for additional products or contractual and usage-based price changes.

Use and Reconciliation of Non-GAAP Financial Measures

In addition to our results determined in accordance with accounting principles generally accepted in the U.S. (“GAAP”), we have calculated non-GAAP cost of revenues, non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development expense, non-GAAP selling and marketing expense, non-GAAP general and administrative expense, non-GAAP operating income, non-GAAP net income, non-GAAP diluted EPS, Adjusted EBITDA, Adjusted EBITDA margin, free cash flow and free cash flow margin, which are each non-GAAP financial measures. We have provided tabular reconciliations of each of these non-GAAP financial measures to its most directly comparable GAAP financial measure.

Management uses these non-GAAP financial measures to understand and compare operating results across accounting periods, for internal budgeting and forecasting purposes, and to evaluate financial performance and liquidity. Our non-GAAP financial measures are presented as supplemental disclosure as we believe they provide useful information to investors and others in understanding and evaluating our results, prospects, and liquidity period-over-period without the impact of certain items that do not directly correlate to our operating performance and that may vary significantly from period to period for reasons unrelated to our operating performance, as well as comparing our financial results to those of other companies. Our definitions of these non-GAAP financial measures may differ from similarly titled measures presented by other companies and therefore comparability may be limited. In addition, other companies may not publish these or similar metrics. Thus, our non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, the financial information prepared in accordance with GAAP financial measures, and should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 to be filed with the SEC.

We calculate these non-GAAP financial measures as follows:

  • Non-GAAP cost of revenues, software subscriptions is determined by adding back to GAAP cost of revenues, software subscriptions, the stock-based compensation expense, and depreciation and amortization of capitalized software costs and acquired intangible assets included in cost of revenues for the respective periods.
  • Non-GAAP cost of revenues, services is determined by adding back to GAAP cost of revenues, services, the stock-based compensation expense included in cost of revenues for the respective periods.
  • Non-GAAP gross profit is determined by adding back to GAAP gross profit the stock-based compensation expense, and depreciation and amortization of capitalized software costs and acquired intangible assets included in cost of revenues for the respective periods.
  • Non-GAAP gross margin is determined by adding back to GAAP gross margin the impact of stock-based compensation expense, and depreciation and amortization of capitalized software costs and acquired intangible assets included in cost of revenues as a percentage of revenues for the respective periods.
  • Non-GAAP research and development expense and non-GAAP general and administrative expenses are determined by adding back to GAAP research and development expense and GAAP general and administrative expense the stock-based compensation expense and severance expense included in the applicable expense categories for the respective periods.
  • Non-GAAP selling and marketing expense is determined by adding back to GAAP selling and marketing expense the stock-based compensation expense and the amortization of acquired intangible assets included in selling and marketing expense for the respective periods.
  • Non-GAAP operating income is determined by adding back to GAAP operating income (loss) the stock-based compensation expense, depreciation and amortization of capitalized software costs and acquired intangible assets, and severance expense included in GAAP operating income (loss) for the respective periods.
  • Non-GAAP net income is determined by adding back to GAAP income (loss) before income taxes the stock-based compensation expense, depreciation and amortization of capitalized software costs and acquired intangible assets – cost of subscription revenues, amortization of acquired intangible assets – selling and marketing expense, and severance expense included in GAAP income (loss) before income taxes for the respective periods to determine non-GAAP income (loss) before income taxes. Non-GAAP income (loss) before income taxes is then adjusted for income taxes calculated using the respective statutory tax rates for applicable jurisdictions, which for purposes of this determination were assumed to be 25.5% and 2.0% for the 2021 and 2020 periods, respectively.
  • Non-GAAP net income per diluted share of Class A and Class B common stock (“Non-GAAP diluted EPS”) is determined by dividing non-GAAP net income by the weighted average shares outstanding of all classes of common stock, inclusive of the impact of common stock equivalents to purchase such common stock, including stock options, restricted stock awards, restricted stock units and employee stock purchase plan shares.
  • Adjusted EBITDA is determined by adding back to GAAP net income (loss) the net interest (income) or expense, income tax expense (benefit), depreciation and amortization of property and equipment, depreciation and amortization of capitalized software costs and acquired intangible assets – cost of subscription revenues, amortization of acquired intangible assets – selling and marketing expense, asset impairments, stock-based compensation expense, severance expense and transaction costs included in GAAP net income (loss) for the respective periods.
  • Adjusted EBITDA margin is determined by dividing Adjusted EBITDA by total revenues for the respective periods.
  • Free cash flow is determined by net cash provided by (used in) operating activities and reducing it for purchases of property and equipment and capitalized software additions for the respective periods.
  • Free cash flow margin is determined by dividing free cash flow by total revenues for the respective periods.

We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure and to view these non-GAAP financial measures in conjunction with the related GAAP financial measures.





Vertex, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

    March 31,   December 31,
(In thousands, except per share data)   2021   2020
Assets            
Current assets:            
Cash and cash equivalents   $ 277,681     $ 303,051  
Funds held for customers     8,745       9,222  
Accounts receivable, net of allowance of $8,059, and $8,592     63,798       77,159  
Prepaid expenses and other current assets     26,696       13,259  
Total current assets     376,920       402,691  
Property and equipment, net of accumulated depreciation     57,408       56,557  
Capitalized software, net of accumulated amortization     34,642       31,989  
Goodwill and other intangible assets     21,553       18,711  
Deferred commissions     11,693       11,743  
Deferred income tax asset     30,373       29,974  
Operating lease right-of-use assets     22,981        
Other assets     2,767       3,263  
Total assets   $ 558,337     $ 554,928  
       
Liabilities and Equity            
Current liabilities:            
Accounts payable   $ 11,115     $ 8,876  
Accrued expenses     15,936       19,176  
Distributions payable     2,700       2,700  
Customer funds obligations     8,798       9,235  
Accrued salaries and benefits     18,065       17,326  
Accrued variable compensation     5,854       22,372  
Deferred compensation, current     2,057       2,057  
Deferred revenue     204,971       207,560  
Current portion of long-term debt           882  
Current portion of operating lease liabilities     4,665        
Current portion of finance lease liabilities     267        
Deferred rent and other           939  
Purchase commitment and contingent consideration liabilities, current     767       845  
Total current liabilities     275,195       291,968  
Deferred compensation, net of current portion     6,048       5,010  
Deferred revenue, net of current portion     13,162       14,702  
Debt, net of current portion           225  
Operating lease liabilities, net of current portion     26,671        
Finance lease liabilities, net of current portion     334        
Purchase commitment and contingent consideration liabilities, net of current portion     10,287       8,905  
Deferred other liabilities     64       8,632  
Total liabilities     331,761       329,442  
Commitments and contingencies            
Stockholders’ equity:            
Preferred shares, $0.001 par value, 30,000 shares authorized; no shares issued and outstanding            
Class A common stock, $0.001 par value, 300,000 shares authorized; 26,972 and 26,327 shares issued and outstanding, respectively     27       26  
Class B common stock, $0.001 par value, 150,000 shares authorized; 120,117 and 120,117 shares issued and outstanding, respectively     120       120  
Additional paid in capital     205,811       206,541  
Retained earnings     24,722       21,926  
Accumulated other comprehensive loss     (4,104 )     (3,127 )
Total stockholders’ equity     226,576       225,486  
Total liabilities and equity   $ 558,337     $ 554,928  





Vertex, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive Income (Loss)

(Unaudited)

    Three Months Ended
    March 31,
(In thousands, except per share data)   2021


  2020


         
Revenues:    
Software subscriptions   $ 83,280     $ 75,760  
Services     14,956       13,485  
Total revenues     98,236       89,245  
Cost of revenues:            
Software subscriptions     25,590       24,684  
Services     11,343       14,778  
Total cost of revenues     36,933       39,462  
Gross profit     61,303       49,783  
Operating expenses:            
Research and development     11,459       13,079  
Selling and marketing     20,150       24,333  
General and administrative     24,852       37,636  
Depreciation and amortization     2,827       2,869  
Other operating (income) expense, net     (129 )     111  
Total operating expenses     59,159       78,028  
Income (loss) from operations     2,144       (28,245 )
Interest expense, net     535       569  
Income (loss) before income taxes     1,609       (28,814 )
Income tax (benefit) expense     (679 )     250  
Net income (loss)     2,288       (29,064 )
Other comprehensive loss from foreign currency translation adjustments and revaluations, net of tax     977       2,998  
Total comprehensive income (loss)   $ 1,311     $ (32,062 )
             
Net income attributable to Class A stockholders   $ 413     $  
Net income per Class A share, basic   $ 0.02     $  
Weighted average Class A common stock, basic     26,458        
Net income attributable to Class A stockholders, diluted   $ 550     $  
Net income per Class A share, diluted   $ 0.01     $  
Weighted average Class A common stock, diluted     38,003        
             
Net income (loss) attributable to Class B stockholders   $ 1,875     $ (29,064 )
Net income (loss) per Class B share, basic   $ 0.02     $ (0.24 )
Weighted average Class B common stock, basic     120,117       120,417  
Net income (loss) attributable to Class B stockholders, diluted   $ 1,738     $ (29,064 )
Net income (loss) per Class B share, diluted   $ 0.01     $ (0.24 )
Weighted average Class B common stock, diluted     120,117       120,417  





Vertex, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

    Three Months Ended
    March 31,
(In thousands)   2021


  2020


Cash flows from operating activities:            
Net income (loss)   $ 2,288     $ (29,064 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities:            
Depreciation and amortization     8,816       7,436  
Provision for subscription cancellations and non-renewals, net of deferred allowance     379       (39 )
Amortization of deferred financing costs     53       221  
Stock-based compensation expense     6,543       34,920  
Deferred income tax (benefit) provision     (615 )      
Non-cash operating lease costs     998        
Other     (14 )     72  
Changes in operating assets and liabilities:            
Accounts receivable     13,810       9,453  
Prepaid expenses and other current assets     (13,437 )     (2,167 )
Deferred commissions     50       634  
Accounts payable     2,258       (2,697 )
Accrued expenses     (3,048 )     (1,042 )
Accrued and deferred compensation     (14,966 )     (19,706 )
Deferred revenue     (5,046 )     (4,307 )
Operating lease liabilities     (1,519 )      
Other     485       (131 )
Net cash used in operating activities     (2,965 )     (6,417 )
Cash flows from investing activities:            
Acquisition of business, net of cash acquired     (6,100 )     (12,318 )
Property and equipment additions     (6,195 )     (5,632 )
Capitalized software additions     (2,221 )     (3,706 )
Net cash used in investing activities     (14,516 )     (21,656 )
Cash flows from financing activities:            
Net increase in customer funds obligations     (438 )     (208 )
Proceeds from line of credit           12,500  
Principal payments on line of credit           (12,500 )
Proceeds from long-term debt           175,000  
Principal payments on long-term debt           (51,041 )
Payments for deferred financing costs, net           (2,904 )
Payments for taxes related to net share settlement of stock-based awards     (7,178 )      
Proceeds from exercise of stock options     147        
Distributions to stockholders           (17,193 )
Payments on financing lease liabilities     (671 )      
Net cash (used in) provided by financing activities     (8,140 )     103,654  
Effect of exchange rate changes on cash, cash equivalents and restricted cash     (226 )     (249 )
Net (decrease) increase in cash, cash equivalents and restricted cash     (25,847 )     75,332  
Cash, cash equivalents and restricted cash, beginning of period     312,273       83,495  
Cash, cash equivalents and restricted cash, end of period   $ 286,426     $ 158,827  
Reconciliation of cash, cash equivalents and restricted cash to the Consolidated Balance Sheets, end of period:            
Cash and cash equivalents   $ 277,681     $ 40,416  
Restricted cash—funds held for stockholder distributions           110,000  
Restricted cash—funds held for customers     8,745       8,411  
Total cash, cash equivalents and restricted cash, end of period   $ 286,426     $ 158,827  





Vertex, Inc. and Subsidiaries

Summary of Non-GAAP Financial Measures

(Unaudited)

    Three Months Ended
    March 31,
(Dollars in thousands, except per share data)   2021


  2020


Non-GAAP cost of revenues, software subscriptions   $ 19,125     $ 16,625  
Non-GAAP cost of revenues, services   $ 10,749     $ 9,540  
Non-GAAP gross profit   $ 68,362     $ 63,080  
Non-GAAP gross margin     69.7 %     70.6 %
Non-GAAP research and development expense   $ 10,898     $ 9,587  
Non-GAAP selling and marketing expense   $ 18,779     $ 17,349  
Non-GAAP general and administrative expense   $ 20,630     $ 20,739  
Non-GAAP operating income   $ 15,357     $ 12,425  
Non-GAAP net income   $ 11,042     $ 11,619  
Non-GAAP diluted EPS   $ 0.07     $ 0.09  
Adjusted EBITDA   $ 18,184     $ 15,294  
Adjusted EBITDA margin     18.5 %     17.1 %
Free cash flow   $ (11,381 )   $ (15,755 )
Free cash flow margin     (11.6 )%     (17.7 )%





Vertex, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

    Three Months Ended
    March 31,
(Dollars in thousands)   2021   2020
Non-GAAP Cost of Revenues, Software Subscriptions:            
Cost of revenues, software subscriptions   $ 25,590     $ 24,684  
Stock-based compensation expense     (560 )     (3,492 )
Depreciation and amortization of capitalized software and acquired intangible assets – cost of subscription revenues     (5,905 )     (4,567 )
Non-GAAP cost of revenues, software subscriptions   $ 19,125     $ 16,625  
             
Non-GAAP Cost of Revenues, Services:            
Cost of revenues, services   $ 11,343     $ 14,778  
Stock-based compensation expense     (594 )     (5,238 )
Non-GAAP cost of revenues, services   $ 10,749     $ 9,540  
             
Non-GAAP Gross Profit:            
Gross profit   $ 61,303     $ 49,783  
Stock-based compensation expense     1,154       8,730  
Depreciation and amortization of capitalized software and acquired intangible assets – cost of subscription revenues     5,905       4,567  
Non-GAAP gross profit   $ 68,362     $ 63,080  
             
Non-GAAP Gross Margin:            
Gross margin     62.5 %     55.7 %
Stock-based compensation expense as a percentage of revenues     1.2 %     9.8 %
Depreciation and amortization of capitalized software and acquired intangible assets – cost of subscription revenues as a percentage of revenues     6.0 %     5.1 %
Non-GAAP gross margin     69.7 %     70.6 %
             
Non-GAAP Research and Development Expense:            
Research and development expense   $ 11,459     $ 13,079  
Stock-based compensation expense     (561 )     (3,492 )
Non-GAAP research and development expense   $ 10,898     $ 9,587  
             
Non-GAAP Selling and Marketing Expense:            
Selling and marketing expense   $ 20,150     $ 24,333  
Stock-based compensation expense     (1,287 )     (6,984 )
Amortization of acquired intangible assets – selling and marketing expense     (84 )      
Non-GAAP selling and marketing expense   $ 18,779     $ 17,349  
             
Non-GAAP General and Administrative Expense:            
General and administrative expense   $ 24,852     $ 37,636  
Stock-based compensation expense     (3,541 )     (15,714 )
Severance expense     (531 )     (1,183 )
Transaction costs     (150 )      
Non-GAAP general and administrative expense   $ 20,630     $ 20,739  





Vertex, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Financial Measures (continued)

(Unaudited)

  Three Months Ended
  March 31,
(In thousands, except per share data) 2021
  2020
Non-GAAP Operating Income:          
Income (loss) from operations $ 2,144     $ (28,245 )
Stock-based compensation expense   6,543       34,920  
Depreciation and amortization of capitalized software and acquired intangible assets – cost of subscription revenues   5,905       4,567  
Amortization of acquired intangible assets – selling and marketing expense   84        
Severance expense   531       1,183  
Transaction costs   150        
Non-GAAP operating income $ 15,357     $ 12,425  
           
Non-GAAP Net Income:          
Income (loss) before income taxes $ 1,609     $ (28,814 )
Stock-based compensation expense   6,543       34,920  
Depreciation and amortization of capitalized software and acquired intangible assets – cost of subscription revenues   5,905       4,567  
Amortization of acquired intangible assets – selling and marketing expense   84        
Severance expense   531       1,183  
Transaction costs   150        
Non-GAAP income before income taxes   14,822       11,856  
Income tax adjustment at statutory rate   (3,780 )     (237 )
Non-GAAP net income $ 11,042     $ 11,619  
           
Non-GAAP Diluted EPS:          
Non-GAAP net income $ 11,042     $ 11,619  
Weighted average Class A and B common stock, diluted   158,120       124,151  
Non-GAAP diluted EPS $ 0.07     $ 0.09  





Vertex, Inc. and Subsidiaries

Reconciliation of GAAP to Non-GAAP Financial Measures (continued)

(Unaudited)

  Three Months Ended
  March 31,
(Dollars in thousands) 2021   2020
Adjusted EBITDA:          
Net income (loss) $ 2,288     $ (29,064 )
Interest expense, net   535       569  
Income tax (benefit) expense   (679 )     250  
Depreciation and amortization – property and equipment   2,827       2,869  
Depreciation and amortization of capitalized software and acquired intangible assets – cost of subscription revenues   5,905       4,567  
Amortization of acquired intangible assets – selling and marketing expense   84        
Stock-based compensation expense   6,543       34,920  
Severance expense   531       1,183  
Transaction costs   150        
Adjusted EBITDA $ 18,184     $ 15,294  
           
Adjusted EBITDA Margin:          
Total revenues $ 98,236     $ 89,245  
Adjusted EBITDA margin   18.5 %     17.1 %

  Three Months Ended
  March 31,
(Dollars in thousands) 2021   2020
Free Cash Flow:          
Cash used in operating activities $ (2,965 )   $ (6,417 )
Property and equipment additions   (6,195 )     (5,632 )
Capitalized software additions   (2,221 )     (3,706 )
Free cash flow $ (11,381 )   $ (15,755 )
           
Free Cash Flow Margin:          
Total revenues $ 98,236     $ 89,245  
Free cash flow margin   (11.6 )%     (17.7 )%



Investor Contact:

Ankit Hira or Ed Yuen
Solebury Trout for Vertex, Inc.
[email protected]
610.312.2890

Media Contact:
Tricia Schafer-Petrecz
Vertex, Inc.
[email protected]
484.595.6142



MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development

PR Newswire

NEW YORK, May 13, 2021 /PRNewswire/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.

As MindMed progresses it’s Discover and Develop efforts for multiple commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed’s product development activities across its entire portfolio of investigational drugs. In addition, Peter will oversee partnerships with Contract Manufacturing Development Organizations and other discovery efforts to support the advancement of MindMed’s proprietary new chemical entities.

Peter joins MindMed from AstraZeneca, where he was the Director of Manufacturing for Inhalation Product Development. Peter previously worked at Pearl Therapeutics (acquired by AstraZeneca in 2013) where he helped pioneer the pharmaceutical development of inhaled combination therapies for highly prevalent respiratory diseases.

Peter holds a dual PhD in Medical Engineering / Medical Physics from Harvard Medical School and Massachusetts Institute of Technology (MIT), where he was a National Institute of Health (NIH) Biomechanics Training Grant Recipient.  Peter also holds a Masters of Science in Mechanical Engineering from MIT.  During his time in academia and the pharmaceutical industry, Peter contributed to numerous peer reviewed articles and patents. 

“MindMed is constantly on the hunt to find the best people to help us shape the future of psychedelic medicine from discovery to delivery. We are excited to have Peter join us on our mission and help us craft a world class pharmaceutical development organization,” said J.R. Rahn, Chief Executive Officer and Co-founder of MindMed.


About MindMed

MindMed is a clinical-stage psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic inspired medicines and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.


Forward-Looking Statements

Certain statements in this news release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding the duration of patent protections for NCE tryptamine and whether such protections will extend beyond the FDA-granted NCE exclusivity period and the impact that NCE tryptamine will have on the Company’s future pipeline.  Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with the securities regulatory authorities in all provinces and territories of Canada which are  available under the Company’s profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Media Contact:

 [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mindmed-bolsters-management-team-appoints-peter-mack-phd-as-vice-president-of-pharmaceutical-development-301290632.html

SOURCE Mind Medicine (MindMed) Inc.

Eltek Sets Earnings Release Date and Conference Call to Report First Quarter 2021 Results on May 20, 2021

Management to hold a conference call at 8:30 a.m. Eastern Time

PR Newswire

PETACH-TIKVA, Israel,, May 13, 2021 /PRNewswire/ — Eltek Ltd. (NASDAQCM: ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of Printed Circuit Boards, announced today that it will release its financial results for the first quarter of 2021, before the market opens on Thursday, May 20, 2021. Eltek’s financial results will be released over the news wires and will be posted on its corporate website at: www.nisteceltek.com.

Eltek Logo

On Thursday, May 20, 2021, at 8:30 a.m. Eastern Time, Eltek will conduct a conference call to discuss the results. The call will feature remarks by Eli Yaffe, Chief Executive Officer and Alon Mualem, Chief Financial Officer.

To participate, please call the following teleconference numbers. Please allow for additional time to connect prior to the call:

United States: 1-888-723-3164
Israel:              03- 9180691
International: +972-3-9180691

 At:


8:30 a.m. Eastern Time



5:30 a.m. Pacific Time



15:30 p.m. Israel Time

A replay of the call will be available through the Investor Info section on Eltek’s corporate website at http://www.nisteceltek.com approximately 24 hours after the conference call is completed and will be archived for 30 days.


About Eltek

Eltek – “Innovation Across the Board”, is a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs), and is the Israeli leader in this industry. PCBs are the core circuitry of most electronic devices. Eltek specializes in the manufacture and supply of complex and high quality PCBs, HDI, multilayered and flex-rigid boards for the high-end market. Eltek is ITAR compliant and has AS-9100 and NADCAP Electronics certifications. Its customers include leading companies in the defense, aerospace and medical industries in Israel, the United States, Europe and Asia.

Eltek was founded in 1970. The Company’s headquarters, R&D, production and marketing center are located in Israel. Eltek also operates through its subsidiary in North America and by agents and distributors in Europe, India, South Africa and South America.

For more information, visit Eltek’s web site at www.nisteceltek.com.


Forward Looking Statement

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to statements regarding expected results in future quarters, risks in product and technology development and rapid technological change, risks associated with the COVID-19 pandemic,  product demand, the impact of competitive products and pricing, market acceptance, the sales cycle, changing economic conditions, the availability of raw materials and other risk factors detailed in the Company’s Annual Report on Form 20-F and other filings with the United States Securities and Exchange Commission.


Investor Contact:



Alon Mualem




Chief Financial Officer
[email protected]

+972-3-9395023

 

Cision View original content:http://www.prnewswire.com/news-releases/eltek-sets-earnings-release-date-and-conference-call-to-report-first-quarter-2021-results-on-may-20-2021-301290595.html

SOURCE Eltek Ltd.

Lion Establishes Lion NFT Limited, Officially Enters the NFT Field

PR Newswire

HONG KONG, May 13, 2021 /PRNewswire/ — Lion Group Holding Ltd. (“Lion” or “the Company”) (NASDAQ: LGHL), operator of an all-in-one trading platform that offers a wide spectrum of products and services with a focus on Chinese investors, today announced it has established Lion NFT Limited (“Lion NFT”) to enter the NFT industry.

Lion NFT is a digital asset company located in the BVI, primarily focused on investment and innovation in digital assets such as non-fungible tokens (“NFTs”). Its parent company holds an MSB license through the U.S. Treasury Department’s Financial Crime Enforcement Agency (FinCEN) and an encrypted commodity operating license through the Dubai Multi Commodity Center (DMCC). Lion NFT engages the world’s top art galleries and museums, as well as IP resources of well-known artists, while working closely with Royal Lion Middle East DMCC, which counts the UAE royal family as an investor. With these resources, Lion NFT can provide services such as digital asset exchange, NFT innovation, issuance and trading on a global scale under supervision. Lion’s NFT trading platform is expected to be launched at the end of the month.

“Lion NFT will offer a full range of services to top artists around the world through NFTs with plans to launch related art works at well-known art festivals. Meanwhile, our technical team has made a major breakthrough in reducing the building cost of NFTs,” said Mr. Wang Chunning (Wilson), Chief Executive Officer of Lion. “Over the next few years, there will be a large number of use cases for NFTs, which will only be possible through encryption. In time, we expect to see a boost in creativity and experimentation within the NFT field.”

About Lion

Lion Group Holding Ltd. (NASDAQ: LGHL) operates an all-in-one trading platform that offers a wide spectrum of products and services with a focus on Chinese investors. Through its state-of-the-art technology, Lion offers contract-for-difference (CFD) trading, insurance brokerage, futures brokerage, and securities brokerage on its platform, which can be accessed through applications available on the iOS, Android, Windows, and macOS systems. Lion’s customers are well-educated and affluent Chinese individual investors residing both inside and outside the PRC as well as institutional clients in Hong Kong. Additional information may be found at http://ir.liongrouphl.com

Forward-Looking Statements

This press release contains, “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Lion’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Lion’s expectations with respect to future performance and anticipated financial impacts of the Business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Lion and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the inability to maintain the listing of the post-acquisition company’s ADSs on NASDAQ following the business combination; (2) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the transactions described herein; (3) the inability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (4) costs related to the business combination; (5) changes in applicable laws or regulations; (6) the possibility that Lion may be adversely affected by other economic, business, and/or competitive factors; and (7) other risks and uncertainties to be identified in the proxy statement/prospectus relating to the business combination, including those under “Risk Factors” therein, and in other filings with the Securities and Exchange Commission (“SEC”) made by Lion. Lion cautions that the foregoing list of factors is not exclusive. Lion cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Lion does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law.


Contacts


Lion Group Holding

Tel: +852 2820 9011
Email: [email protected]


ICR, LLC


William Zima

Tel: +1 203 682 8233
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/lion-establishes-lion-nft-limited-officially-enters-the-nft-field-301290500.html

SOURCE Lion Group Holding Ltd.

Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021

PR Newswire

CRANBURY, N.J., May 13, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 17, 2021 at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development.


Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Q3 Fiscal Year 2021 Results Press Release               

5/17/2021 at 7:30 a.m. ET

Q3 Fiscal Year 2021 Conference Call-Live                  

5/17/2021 at 11:00 a.m. ET

US/Canada Dial-In Number:                                          

1-866-248-8441

International Dial-In Number:                                          

1-856-344-9206

Conference ID:                                                                 

6765353

Q3 Fiscal Year 2021 Conference Call-Replay               

5/17/2021-5/24/2021

US/Canada Dial-In Number:                                           

1-888-203-1112

International Dial-In Number:                                           

1-719-457-0820

Replay Passcode:                                                             

6765353

Audio Webcast Live and Replay Access                             


http://www.palatin.com

The audio webcast and replay can be accessed by logging on to the “Investors-Webcasts” section of Palatin’s website at http://www.palatin.com.


About Palatin

Palatin is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-to-report-third-quarter-fiscal-year-2021-results-teleconference-and-webcast-to-be-held-on-may-17-2021-301290633.html

SOURCE Palatin Technologies, Inc.

Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates

PR Newswire

WARRINGTON, Pa., May 13, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.


Key Business and Financial Updates

  • Expanded the participating countries and sites in the Company’s Phase 2 global clinical study of istaroxime for the treatment of Early Cardiogenic Shock in severe acute heart failure patients. Cardiogenic shock is a severe form of heart failure marked by critically low blood pressure. This study builds upon observations from the acute heart failure program and will assess the ability of istaroxime to improve blood pressure in these patients and is expected to be completed in the second half of 2021.
  • Dosed the first patient in its Phase 2 clinical trial studying lucinactant, the Company’s KL4 surfactant, in acute lung injury in adults with COVID-19 associated acute respiratory distress syndrome (ARDS). The study is designed to evaluate key safety and physiological measures and is expected to be completed in Q3 2021.
  • Completed an equity financing raising approximately $30.0 million in gross proceeds during the first quarter of 2021, before deducting underwriting discounts and commissions and other estimated offering expenses. Net proceeds from the offering were approximately $27.4 million.
  • Announced pursuit of additional expedited patent protection for our lead asset istaroxime with the filing of a Track One prioritized patent application with the U.S. Patent and Trademark Office for a patent stemming from an application previously filed under the Patent Cooperation Treaty. Under the Track One program, the new istaroxime patent is expected to receive review and final disposition within a year of priority status being granted, rather than the customary three-year examination for non-prioritized examinations.
  • Extended the scientific collaboration with the University of Milan-Bicocca for further characterization and development of the Company’s oral SERCA2a compounds for the potential treatment of chronic and acute human heart failure.

“With additional countries and sites opening and dosing patients in our Phase 2 global clinical study of istaroxime for the treatment of Early Cardiogenic Shock in severe acute heart failure patients and the first patient dosed in our Phase 2 study of lucinactant in acute lung injury in adults with COVID-19 associated ARDS, our first quarter was off to a very productive start,” said Craig Fraser, President and Chief Executive Officer of Windtree. “As we look to the rest of the year, we see several potential value-creating milestones with data readouts anticipated in both Phase 2 trials. Additionally, we are actively engaged on the business development front, and are encouraged by the level of interest. Importantly, with the successful completion of a financing this quarter, our balance sheet provides the runway to continue to help fuel these current and planned development activities. We are focused on execution and a year of important milestones.”


Select Financial Results for the First Quarter ended March 31, 2021

For the first quarter ended March 31, 2021, the Company reported an operating loss of $9.1 million, compared to an operating loss of $6.7 million in the first quarter of 2020.

Research and development expenses were $4.4 million for the first quarter of 2021, compared to $3.5 million for the first quarter of 2020. The increase in research and development expenses is primarily due to costs related to the clinical development of istaroxime.

General and administrative expenses for the first quarter of 2021 were $4.7 million, compared to $3.2 million for the first quarter of 2020.

The Company reported a net loss of $9.0 million ($0.51 per basic share) on 17.7 million weighted-average common shares outstanding for the first quarter ended March 31, 2021, compared to a net loss of $6.5 million ($0.48 per basic share) on 13.7 million weighted average common shares outstanding for the comparable period in 2020.

As of March 31, 2021, the Company reported cash and cash equivalents of $38.5 million.

Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which will be filed with the Securities and Exchange Commission on May 13, 2021, which includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee’s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company’s website at www.windtreetx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company’s clinical trials or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime, AEROSURF®, KL4 surfactant and the Company’s other product candidates; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, aerosol delivery systems (ADS) and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the FDA or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company’s product candidates, if approved. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release
.

 


Tables to Follow

+++++++++

 


Condensed Consolidated Balance Sheets


(in thousands, except share and per share data)


Three Months Ended


March 31,


2021


2020

Unaudited


ASSETS

Current Assets:

Cash and cash equivalents

$            38,490

$            16,930

Prepaid expenses and other current assets

851

1,188

Total current assets

39,341

18,118

Property and equipment, net

879

924

Restricted cash

154

154

Operating lease right-of-use assets

2,747

917

Intangible assets

77,090

77,090

Goodwill

15,682

15,682

Total assets

$          135,893

$          112,885


LIABILITIES & STOCKHOLDERS’ EQUITY

Current Liabilities:

Accounts payable

$                 939

$              1,161

Accrued expenses

3,744

3,813

Operating lease liabilities – current portion

392

805

Loans payable – current portion

2,409

352

Total current liabilities

7,484

6,131

Operating lease liabilities – non-current portion

2,438

201

Loans payable – non-current portion

2,423

Restructured debt liability – contingent milestone payments

15,000

15,000

Other liabilities

2,800

2,800

Deferred tax liabilities

16,683

16,778

Total liabilities

44,405

43,333

Stockholders’ Equity:

Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2021 and December 31, 2020

Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2021 and December 31, 2020; 26,257,089 and 16,921,506 shares issued at March 31, 2021 and December 31, 2020, respectively; 26,257,065 and 16,921,482 shares outstanding at March 31, 2021 and December 31, 2020, respectively

26

17

Additional paid-in capital

821,165

790,277

Accumulated deficit

(726,649)

(717,688)

Treasury stock (at cost); 24 shares

(3,054)

(3,054)

Total stockholders’ equity

91,488

69,552

Total liabilities & stockholders’ equity

$          135,893

$          112,885

 


Condensed Consolidated Statements of Operations


(in thousands, except per share data)


Three Months Ended


March 31,


2021


2020

Expenses:

Research and development

$         4,410

$         3,461

General and administrative

4,669

3,242

Total operating expenses

9,079

6,703

Operating loss

(9,079)

(6,703)

Other (expense) income:

Interest income

50

89

Interest expense

(41)

(44)

Other income, net

109

124

Total other (expense) income, net

118

169

Net loss

$        (8,961)

$        (6,534)

Net loss per common share

Basic and diluted

$          (0.51)

$          (0.48)

Weighted average number of common shares outstanding

Basic and diluted

17,695

13,697

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/windtree-therapeutics-reports-first-quarter-2021-financial-results-and-provides-key-business-updates-301290567.html

SOURCE Windtree Therapeutics, Inc.

FluroTest and SNC-Lavalin Sign MoU to Bring Saliva Sample-Based SARS-CoV-2 Testing Solution System to Market in Canada and Beyond

PR Newswire

CALGARY, AB and MONTRÉAL, May 13, 2021 /PRNewswire/ – FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems (“FluroTest” or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces it has signed a strategic Memorandum of Understanding dated May 6, 2021 (“MoU”) with SNC-Lavalin (TSX: SNC) to support pre-deployment, commercialization and operations phases of FluroTest’s high-volume COVID-19 rapid antigen test platform.

Under the terms of the MoU, SNC-Lavalin will provide support to FluroTest in their mandate to bring its rapid antigen testing system to market by providing services during regulatory submission, grant application, business development, robotics/skid design & assembly, room design/build, site installation, commissioning & validation as well as program & project management. SNC-Lavalin may continue thereafter executing site operations and support of the platform. FluroTest will provide all necessary technical information and support. Both parties will work together to deliver FluroTest’s solution. The MoU term is for one year and does not contemplate any financial considerations.

FluroTest’s high-volume antigen system is designed to facilitate very fast and accurate point of access testing of individuals by leveraging the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing. High-risk pandemic environments supported will include athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, manufacturing facilities, schools and colleges, hospitals and large healthcare facilities, transportation and distribution hubs and other large businesses. The Company is presently engaged in clinical trials and plans submissions for Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) and from Health Canada for an Interim Order Authorization.

“We are proud to support FluroTest in the deployment of their innovative solution to help stop the spread of COVID-19 and improve the health of our communities by leveraging SNC-Lavalin’s markets and global expertise,” said Normand Dubuc, Vice-President, General Manager, Industrial Solutions at SNC-Lavalin. “We appreciate FluroTest’s dedication to provide this affordable, adaptable and portable solution as an important step in providing individuals with the information they need to get back to leading a full and healthy life.”

The Life Sciences group of SNC-Lavalin has been designing and delivering pharmaceutical, biotech and medical device research and production facilities around the world for over 30 years Their highly skilled team dedicated to this regulatory environment offers end-to-end services from design to construction with validation and quality assurance. They have delivered production sites in fast-track mode, and supported operations for some of the biggest names in pharma, while accompanying innovative start-ups through their journey to commercial manufacturing.

“Partnering with an established company like SNC-Lavalin will help us expedite commercialization, access vast supply chain expertise and help establish the FluroTest Pandemic Defense Platform as the preferred point of access testing solution,” said Bill Phelan, CEO of FluroTest. “As Canada and the U.S. ramp up testing to serve vulnerable populations, we look forward to working with a professional services group known for creative solutions as we  jointly deliver trusted point of access testing for unpredictable times.” 

Readers are cautioned that, although FluroTest has achieved proof of concept prototype, the testing method and device is still in the pre-approval stage and accordingly FluroTest is not currently making any express or implied claims that the technology can, or will be able to, accurately detect the COVID-19 virus.

Ab
out FluroTech (TSXV: TEST) (OTCQB: FLURF)

The goal of FluroTech’s research and technology is to develop detection methods which are high speed, sensitive, specific and easy-to-use. By combining FluroTech’s proprietary spectroscopy-based technology with laboratory robotics automation and cloud computing, FluroTech, through the application of its technology and investment in FluroTest Diagnostics Systems Ltd. (“FluroTest”), the interests in which have been disclosed in previous press releases, has created a unique solution addressing the current and future pandemics. Using technology that was first developed at the University of Calgary, the FluroTest SARS-CoV-2 test is designed to identify patients with active virus infection; this is not necessarily the case for most of the currently approved tests that are meant to identify patients with SARS-CoV-2 nucleic acid.

About FluroTest Diagnostic Systems Ltd.

FluroTest, a diagnostics technology leader in surge-scale rapid antigen testing for the detection of SARS-CoV2 and other pathogens, is developing a pandemic defense and economic recovery system purpose-built for businesses and special-needs populations requiring fast and highly accurate testing for significant numbers of people. Unlike individual or low-throughput tests, FluroTest’s system is designed to be well-suited for high-traffic, high-risk pandemic environments including schools and colleges, hospitals and large healthcare facilities, athletic stadiums and performance venues, airline and cruise ship terminals, corporate campuses, shopping centers, manufacturing facilities, transportation and distribution hubs and other large business and retail locations. Created to support executive business continuity efforts and public well-being, the system combines and leverages the disciplines of robotics automation, biochemistry, fluorescence detection and cloud computing — processing thousands of tests per hour while delivering accurate, digitally verifiable results to a test taker’s mobile device within 5 minutes. To learn more, visit FluroTest.com.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s perspective financial performance or financial position. The forward-looking information in this news release includes disclosure about the ability of the Company’s testing devices to accurately and quickly detect COVID-19 and to process large numbers of samples in short time frames, the benefits of and demand for the Company’s testing devices, its efforts to obtain approval of the FDA and Health Canada, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Diagnostics Systems Ltd which owns a 100% interest in FluroTest LLC. The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the ability to obtain FDA and Health Canada approvals, the demand for its COVID-19 testing devices and their ability to perform as expected, its potential partnership with a major U.S. based healthcare system and finalizing plans to conduct clinical trials and its intent to amalgamate with FluroTest Diagnostics Systems Ltd which owns a 100% interest in FluroTest LLC  and to obtain the regulatory approvals required in connection with the same, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors described in the Corporation’s Annual Information Form under the heading “Risk Factors”, the failure to develop and commercialize its testing devices in a timely manner or at all, the failure to recognize the anticipated benefits from the devices, the failure to obtain FDA or Health Canada approval for its products, the risk that regulatory approvals will not be received and the risk that changing circumstances will result in the decrease in demand for FluroTest’s products. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/flurotest-and-snc-lavalin-sign-mou-to-bring-saliva-sample-based-sars-cov-2-testing-solution-system-to-market-in-canada-and-beyond-301290409.html

SOURCE FluroTech Ltd.

Signet Jewelers Announces Timing Of Fiscal 2022 First Quarter Earnings Release And Conference Call

PR Newswire

HAMILTON, Bermuda, May 13, 2021 /PRNewswire/ — Signet Jewelers Limited (NYSE: SIG) intends to announce its first quarter results at approximately 7:00 a.m. ET on Thursday, June 10, 2021.

On that date there will be a conference call at 8:30 a.m. ET and a simultaneous audio webcast available at www.signetjewelers.com

The call details are:

Toll Free US Dial-in:  1-844-750-4866

International Dial-In: +1 412-317-5109

Conference call participants may also pre-register at:

https://dpregister.com/sreg/10156193/e840e1f9ea      

Contact:

Vinnie Sinisi

SVP Investor Relations & Treasury
+1 330 665 6530
[email protected]

Colleen Rooney

Chief Communications Officer                              
+1 330 668 5932
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/signet-jewelers-announces-timing-of-fiscal-2022-first-quarter-earnings-release-and-conference-call-301290265.html

SOURCE Signet Jewelers Ltd.